GnRH agonists in the treatment of endometriosis.

Acta Europaea fertilitatis · 1988 · vol. 19(1) , pp. 5–12 · PMID:3046216 · W2416496368
article OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed
AI-generated summary by claude@2026-06, 2026-06-07

GnRH agonists treat endometriosis by causing reversible hypogonadotropic hypogonadism, but their superiority and long-term efficacy for fertility and pain recurrence remain unclear.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

GnRH agonists, synthetic peptide analogs of GnRH, desensitize pituitary receptors for the native molecule, thus causing reversible hypogonadotropic hypogonadism. Numerous clinical studies have suggested that these compounds are efficacious in the treatment of endometriosis, but it is not clear whether they are superior to the other drugs used in treatment of this disease. The frequency of recurrence of pain symptoms at the end of treatment is high and the data on recovery of fertility are conflicting. Long-term administration of GnRH agonists is a safe and well tolerated treatment but its role in the management of endometriosis is still not well defined.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Pituitary Hormone-Releasing Hormones Animals Clinical Trials as Topic Endometriosis Female Humans Pituitary Hormone-Releasing Hormones Pituitary Hormone-Releasing Hormones Pituitary Hormone-Releasing Hormones Pituitary Hormone-Releasing Hormones

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (3)

Cited by (3)

Source provenance

europepmc
last seen: 2026-06-20T06:14:18.781669+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:09:25.758913+00:00
License: CC0 · commercial use OK